Skip to main content

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

National Stock Exchange of India Healthcare Drug Manufacturers - Specialty & Generic
62.2Fair

ValueMarkers Composite Index

Top 88%#5,459 of 45,191
Undervalued

73% below intrinsic value ($72)

UndervaluedFair ValueOvervalued
Piotroski
8/9
Strong
Beneish
-2.26
Low Risk
Altman
15.33
Safe
DCF Value
$72
Undervalued
ROIC
14.8%
Adequate
P/E
37.2
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.

CEO: Dilip Shantilal Shanghvi43,000 employeesINwww.sunpharma.com

Deep Dive Analysis

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.